A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Chicago
Massachusetts General Hospital
Columbia University
BeOne Medicines
Mayo Clinic
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Baylor College of Medicine
National Institutes of Health Clinical Center (CC)
BeOne Medicines
Eli Lilly and Company
M.D. Anderson Cancer Center
Acerta Pharma BV
Iovance Biotherapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Acerta Pharma BV
Ohio State University Comprehensive Cancer Center
University of Nebraska
University of California, San Diego
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
Lomond Therapeutics Holdings, Inc.
AbbVie
AstraZeneca
National Cancer Institute (NCI)
French Innovative Leukemia Organisation
AbbVie
BeOne Medicines
Oncology Institute of Southern Switzerland
Hoffmann-La Roche
Thomas Jefferson University
AbbVie
Regeneron Pharmaceuticals
UNC Lineberger Comprehensive Cancer Center
University of California, San Diego
Genentech, Inc.
Boryung Pharmaceutical Co., Ltd
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Center for International Blood and Marrow Transplant Research
Cancer Trials Ireland
Masonic Cancer Center, University of Minnesota
AbbVie
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
American Regent, Inc.